Cargando…

Loss of the GPI‐anchor in B‐lymphoblastic leukemia by epigenetic downregulation of PIGH expression

Adult B‐lymphoblastic leukemia (B‐ALL) is a hematological malignancy characterized by genetic heterogeneity. Despite successful remission induction with classical chemotherapeutics and novel targeted agents, enduring remission is often hampered by disease relapse due to outgrowth of a pre‐existing s...

Descripción completa

Detalles Bibliográficos
Autores principales: Loeff, Floris C., Rijs, Kevin, van Egmond, Esther H. M., Zoutman, Willem H., Qiao, Xiaohang, Kroes, Wilhelmina G. M., Veld, Sabrina A. J., Griffioen, Marieke, Vermeer, Maarten H., Neefjes, Jacques, Frederik Falkenburg, J. H., Halkes, Constantijn J. M., Jedema, Inge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587464/
https://www.ncbi.nlm.nih.gov/pubmed/30370942
http://dx.doi.org/10.1002/ajh.25337
_version_ 1783429070995849216
author Loeff, Floris C.
Rijs, Kevin
van Egmond, Esther H. M.
Zoutman, Willem H.
Qiao, Xiaohang
Kroes, Wilhelmina G. M.
Veld, Sabrina A. J.
Griffioen, Marieke
Vermeer, Maarten H.
Neefjes, Jacques
Frederik Falkenburg, J. H.
Halkes, Constantijn J. M.
Jedema, Inge
author_facet Loeff, Floris C.
Rijs, Kevin
van Egmond, Esther H. M.
Zoutman, Willem H.
Qiao, Xiaohang
Kroes, Wilhelmina G. M.
Veld, Sabrina A. J.
Griffioen, Marieke
Vermeer, Maarten H.
Neefjes, Jacques
Frederik Falkenburg, J. H.
Halkes, Constantijn J. M.
Jedema, Inge
author_sort Loeff, Floris C.
collection PubMed
description Adult B‐lymphoblastic leukemia (B‐ALL) is a hematological malignancy characterized by genetic heterogeneity. Despite successful remission induction with classical chemotherapeutics and novel targeted agents, enduring remission is often hampered by disease relapse due to outgrowth of a pre‐existing subclone resistant against the treatment. In this study, we show that small glycophosphatidylinositol (GPI)‐anchor deficient CD52‐negative B‐cell populations are frequently present already at diagnosis in B‐ALL patients, but not in patients suffering from other B‐cell malignancies. We demonstrate that the GPI‐anchor negative phenotype results from loss of mRNA expression of the PIGH gene, which is involved in the first step of GPI‐anchor synthesis. Loss of PIGH mRNA expression within these B‐ALL cells follows epigenetic silencing rather than gene mutation or deletion. The coinciding loss of CD52 membrane expression may contribute to the development of resistance to alemtuzumab (ALM) treatment in B‐ALL patients resulting in the outgrowth of CD52‐negative escape variants. Additional treatment with 5‐aza‐2′‐deoxycytidine may restore expression of CD52 and revert ALM resistance.
format Online
Article
Text
id pubmed-6587464
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-65874642019-07-02 Loss of the GPI‐anchor in B‐lymphoblastic leukemia by epigenetic downregulation of PIGH expression Loeff, Floris C. Rijs, Kevin van Egmond, Esther H. M. Zoutman, Willem H. Qiao, Xiaohang Kroes, Wilhelmina G. M. Veld, Sabrina A. J. Griffioen, Marieke Vermeer, Maarten H. Neefjes, Jacques Frederik Falkenburg, J. H. Halkes, Constantijn J. M. Jedema, Inge Am J Hematol Research Articles Adult B‐lymphoblastic leukemia (B‐ALL) is a hematological malignancy characterized by genetic heterogeneity. Despite successful remission induction with classical chemotherapeutics and novel targeted agents, enduring remission is often hampered by disease relapse due to outgrowth of a pre‐existing subclone resistant against the treatment. In this study, we show that small glycophosphatidylinositol (GPI)‐anchor deficient CD52‐negative B‐cell populations are frequently present already at diagnosis in B‐ALL patients, but not in patients suffering from other B‐cell malignancies. We demonstrate that the GPI‐anchor negative phenotype results from loss of mRNA expression of the PIGH gene, which is involved in the first step of GPI‐anchor synthesis. Loss of PIGH mRNA expression within these B‐ALL cells follows epigenetic silencing rather than gene mutation or deletion. The coinciding loss of CD52 membrane expression may contribute to the development of resistance to alemtuzumab (ALM) treatment in B‐ALL patients resulting in the outgrowth of CD52‐negative escape variants. Additional treatment with 5‐aza‐2′‐deoxycytidine may restore expression of CD52 and revert ALM resistance. John Wiley & Sons, Inc. 2018-11-25 2019-01 /pmc/articles/PMC6587464/ /pubmed/30370942 http://dx.doi.org/10.1002/ajh.25337 Text en © 2018 The Authors. American Journal of Hematology published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Articles
Loeff, Floris C.
Rijs, Kevin
van Egmond, Esther H. M.
Zoutman, Willem H.
Qiao, Xiaohang
Kroes, Wilhelmina G. M.
Veld, Sabrina A. J.
Griffioen, Marieke
Vermeer, Maarten H.
Neefjes, Jacques
Frederik Falkenburg, J. H.
Halkes, Constantijn J. M.
Jedema, Inge
Loss of the GPI‐anchor in B‐lymphoblastic leukemia by epigenetic downregulation of PIGH expression
title Loss of the GPI‐anchor in B‐lymphoblastic leukemia by epigenetic downregulation of PIGH expression
title_full Loss of the GPI‐anchor in B‐lymphoblastic leukemia by epigenetic downregulation of PIGH expression
title_fullStr Loss of the GPI‐anchor in B‐lymphoblastic leukemia by epigenetic downregulation of PIGH expression
title_full_unstemmed Loss of the GPI‐anchor in B‐lymphoblastic leukemia by epigenetic downregulation of PIGH expression
title_short Loss of the GPI‐anchor in B‐lymphoblastic leukemia by epigenetic downregulation of PIGH expression
title_sort loss of the gpi‐anchor in b‐lymphoblastic leukemia by epigenetic downregulation of pigh expression
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587464/
https://www.ncbi.nlm.nih.gov/pubmed/30370942
http://dx.doi.org/10.1002/ajh.25337
work_keys_str_mv AT loeffflorisc lossofthegpianchorinblymphoblasticleukemiabyepigeneticdownregulationofpighexpression
AT rijskevin lossofthegpianchorinblymphoblasticleukemiabyepigeneticdownregulationofpighexpression
AT vanegmondestherhm lossofthegpianchorinblymphoblasticleukemiabyepigeneticdownregulationofpighexpression
AT zoutmanwillemh lossofthegpianchorinblymphoblasticleukemiabyepigeneticdownregulationofpighexpression
AT qiaoxiaohang lossofthegpianchorinblymphoblasticleukemiabyepigeneticdownregulationofpighexpression
AT kroeswilhelminagm lossofthegpianchorinblymphoblasticleukemiabyepigeneticdownregulationofpighexpression
AT veldsabrinaaj lossofthegpianchorinblymphoblasticleukemiabyepigeneticdownregulationofpighexpression
AT griffioenmarieke lossofthegpianchorinblymphoblasticleukemiabyepigeneticdownregulationofpighexpression
AT vermeermaartenh lossofthegpianchorinblymphoblasticleukemiabyepigeneticdownregulationofpighexpression
AT neefjesjacques lossofthegpianchorinblymphoblasticleukemiabyepigeneticdownregulationofpighexpression
AT frederikfalkenburgjh lossofthegpianchorinblymphoblasticleukemiabyepigeneticdownregulationofpighexpression
AT halkesconstantijnjm lossofthegpianchorinblymphoblasticleukemiabyepigeneticdownregulationofpighexpression
AT jedemainge lossofthegpianchorinblymphoblasticleukemiabyepigeneticdownregulationofpighexpression